Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial

PURPOSE: The mitogen-activated extracellular signal-related kinase kinase (MEK) is a member of the RAS/RAF/MEK/ERK signalling cascade, which is commonly activated in melanoma. Direct inhibition of MEK inhibits ERK signalling. METHODS: We conducted a multicentre, first-in-human, three-part study (dos...

詳細記述

保存先:
書誌詳細
主要な著者: Falchook, Gerald S, Lewis, Karl D, Infante, Jeffrey R, Gordon, Michael S, Vogelzang, Nicholas J, DeMarini, Douglas J, Sun, Peng, Moy, Christopher, Szabo, Stephen A., Roadcap, Lori T, Peddareddigari, Vijay G R, Lebowitz, Peter F, Le, Ngocdiep T, Burris, Howard A, Messersmith, Wells A, O'Dwyer, Peter J, Kim, Kevin B., Flaherty, Keith, Bendell, Johanna C., Gonzalez, Rene, Kurzrock, Razelle, Fecher, Leslie A
フォーマット: Artigo
言語:Inglês
出版事項: 2012
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4109286/
https://ncbi.nlm.nih.gov/pubmed/22805292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(12)70269-3
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料